EntryPoint Capital’s PTC Therapeutics PTCT Stock Holding History

EntryPoint Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$379K	Hold	4,650	–	–	0.09%	440
2026 Q1	$317K	Buy	+4,650	New	+$329K	0.09%	443
2025 Q4	–	Sell	-7,384	Closed	-$453K	–	822
2025 Q3	$453K	Buy	7,384 +574	+8%	+$29.9K	0.18%	203
2025 Q2	$333K	Buy	+6,810	New	+$323K	0.17%	233
2024 Q4	–	Sell	-8,836	Closed	-$328K	–	920
2024 Q3	$328K	Buy	8,836 +4,781	+118%	+$160K	0.19%	211
2024 Q2	$124K	Buy	4,055 +1,794	+79%	+$58.1K	0.06%	693
2024 Q1	$65.8K	Sell	2,261 -3,401	-60%	-$95.3K	0.06%	625
2023 Q4	$156K	Buy	+5,662	New	+$129K	0.15%	174

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

EntryPoint Capital's PTCT Position: Q2 2026 in Review

EntryPoint Capital held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 4,650 shares worth $379K. The position accounts for 0.09% of the portfolio, ranked #440.

EntryPoint Capital first reported a position in PTCT in Q4 2023 and has held it in 8 quarters since. The position peaked at $453K in Q3 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

EntryPoint Capital held 4,650 shares of PTC Therapeutics worth $379K as of Q2 2026.
EntryPoint Capital left its PTC Therapeutics share count unchanged in Q2 2026.
PTC Therapeutics made up 0.09% of EntryPoint Capital's portfolio in Q2 2026, its #440 holding.
EntryPoint Capital first reported a position in PTC Therapeutics in Q4 2023 and has held it in 8 quarters since.
EntryPoint Capital's PTC Therapeutics position peaked at $453K in Q3 2025.
383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.